Back to mobile site

More on GENB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (12/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:GENB)
Delayed: 13.05 +0.15 (1.16%)
Prev. Close $12.90  
Open$13.04 
52 Wk High$ 
52 Wk Low$ 
Day High$13.17 
Day Low$12.80 
P/E N/A  
EPS$ 
Volume31,423 

Friends, Peers and Foes (?): ZEAL, ALNY, ARVN, ARWR, CAPR (more...)

Oct 14, 2026 09:45 AM AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
Oct 13, 2026 04:30 PM Generate Biomedicines and Zealand Pharma strike AI drug deal
Oct 13, 2026 04:30 PM Zealand Pharma and Generate Biomedicines strike AI drug deal
Oct 13, 2026 04:30 PM Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Oct 13, 2026 04:30 PM Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Oct 5, 2026 06:41 AM H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)
Oct 1, 2026 07:03 AM Roswell Park begins first human trial of AI-designed CAR T therapy
Oct 1, 2026 07:00 AM Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Sep 9, 2026 07:28 AM H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)
Sep 8, 2026 07:09 AM Generate Biomedicines Inc. to Participate in September Investor Conferences
View All Articles

Entities mentioned with GENB

View All Entities